Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

People with lupus are at an increased risk of depression. Lupus is a chronic condition with recurring symptoms that can ...

The event raised awareness for those with lupus, a chronic autoimmune disease that leads the body’s immune system to attack ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

The Lupus Foundation of America is a nonprofit whose mission is to "improve the quality of life for all people affected by ...

The two Malmö artists behind Anonymouse, the street art collective which charmed the world with mouse-sized bistros, cafés, ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Competition leaders the Saitama Wild Knights and defending champions Brave Lupus Tokyo played to a gripping 28-28 deadloc ...

The following is a summary of “Barriers and facilitators to sustaining a lupus patient decision aid in regular rheumatology ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...